Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL96921 | 1.00 | MAOB (0.70) | MAOBMAPK1ALDH1A1LMNATRPA1 | |
| SCHEMBL27571915 | 0.98 | MAOB (0.67) | MAOBMAPK1ALDH1A1LMNATRPA1 | |
| SCHEMBL95432 | 0.90 | MAOB (0.68) | MAOBMAPK1ALDH1A1LMNATRPA1 | |
| SCHEMBL95433 | 0.90 | MAOB (0.68) | MAOBMAPK1ALDH1A1LMNATRPA1 | |
| SCHEMBL23457944 | 0.87 | MAOB (0.93) | MAOBMAPK1ALDH1A1LMNATRPA1 | |
| SCHEMBL17312322 | 0.87 | MAOB (0.93) | MAOBMAPK1ALDH1A1LMNATRPA1 | |
| SCHEMBL8927957 | 0.87 | MAOB (0.93) | MAOBMAPK1ALDH1A1LMNATRPA1 | |
| SCHEMBL133926 | 0.87 | MAOB (0.93) | MAOBMAPK1ALDH1A1LMNATRPA1 | |
| SCHEMBL250402 | 0.87 | MAOB (0.93) | MAOBMAPK1ALDH1A1LMNATRPA1 | |
| SCHEMBL466299 | 0.87 | MAOB (0.93) | MAOBMAPK1ALDH1A1LMNATRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0670041-B1 | FLUORESCENCE ENERGY TRANSFER AND INTRAMOLECULAR ENERGY TRANSFER IN PARTICLES USING NOVEL COMPOUNDS | BIOSITE DIAGNOSTICS INC (US) | 2002-01-30 | — | — | EP | claimed |
| US-6251687-B1 | PARTICLE CONTAINING ENERGY DONOR AND ENERGY ACCEPTOR | BIOSITE DIAGNOSTICS, INC. | 2001-06-26 | — | — | US | claimed |
| US-6238931-B1 | PARTICLES WITH ENERGY DONORS AND ACCEPTORS AS WELL AS PROTEINS, POLYPEPTIDES, NUCLEIC ACIDS, OR LIGAND ANALOGUES BOUND TO SURFACE; WITH REDUCED QUENCHING AND IMPROVED FLUORESCENCE INTENSITIES; IMMUNOASSAYS | BIOSITE DIAGNOSTICS, INC. | 2001-05-29 | — | — | US | claimed |
| EP-0670041-A4 | FLUORESCENCE ENERGY TRANSFER AND INTRAMOLECULAR ENERGY TRANSFER IN PARTICLES USING NOVEL COMPOUNDS. | BIOSITE DIAGNOSTICS INC (US) | 1997-11-05 | — | — | EP | claimed |
| JP-H08503994-A | — | — | 1996-04-30 | — | — | JP | claimed |
| EP-0670041-A1 | FLUORESCENCE ENERGY TRANSFER AND INTRAMOLECULAR ENERGY TRANSFER IN PARTICLES USING NOVEL COMPOUNDS | BIOSITE DIAGNOSTICS INC. (US) | 1995-09-06 | — | — | EP | claimed |
| WO-1995008772-A1 | FLUORESCENCE ENERGY TRANSFER AND INTRAMOLECULAR ENERGY TRANSFER IN PARTICLES USING NOVEL COMPOUNDS | BIOSITE DIAGNOSTICS INCORPORATED (US) | 1995-03-30 | — | — | WO | claimed |
| CN-109891326-B | Electrophotographic photoreceptor, process cartridge, and image forming apparatus | 京瓷办公信息系统株式会社 | 2022-08-02 | — | — | CN | disclosed |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| US-20200281951-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-09-10 | — | — | US | disclosed |
| US-10761440-B2 | Electrophotographic photosensitive member, process cartridge, and image forming apparatus | KYOCERA DOCUMENT SOLUTIONS INC. (JP) | 2020-09-01 | — | — | US | disclosed |
| US-10603331-B2 | Method of treating disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-03-31 | — | — | US | disclosed |
| US-20190310562-A1 | ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER, PROCESS CARTRIDGE, AND IMAGE FORMING APPARATUS | KYOCERA DOCUMENT SOLUTIONS INC. (JP) | 2019-10-10 | — | — | US | disclosed |
| US-5824799-A | A SILICON FLUORESCENT DYES FOR DETECTING ANALYTE IN IMMUNOASSAYS | BIOSITE DIAGNOSTICS INCORPORATED (US) | 1998-10-20 | — | — | US | disclosed |
| US-5763189-A | Fluorescence energy transfer and intramolecular energy transfer in particles using novel compounds | BIOSITE DIAGNOSTICS INCORPORATED (US) | 1998-06-09 | — | — | US | disclosed |
| EP-0820489-A1 | HYBRID PHTHALOCYANINE DERIVATIVES AND THEIR USES | BIOSITE DIAGNOSTICS INC. (US) | 1998-01-28 | — | — | EP | disclosed |
| EP-0670041-A4 | FLUORESCENCE ENERGY TRANSFER AND INTRAMOLECULAR ENERGY TRANSFER IN PARTICLES USING NOVEL COMPOUNDS. | BIOSITE DIAGNOSTICS INC (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996029367-A1 | HYBRID PHTHALOCYANINE DERIVATIVES AND THEIR USES | BIOSITE DIAGNOSTICS INCORPORATED (US) | 1996-09-26 | — | — | WO | disclosed |
| EP-0670041-A1 | FLUORESCENCE ENERGY TRANSFER AND INTRAMOLECULAR ENERGY TRANSFER IN PARTICLES USING NOVEL COMPOUNDS | BIOSITE DIAGNOSTICS INC. (US) | 1995-09-06 | — | — | EP | disclosed |
| WO-1995008772-A1 | FLUORESCENCE ENERGY TRANSFER AND INTRAMOLECULAR ENERGY TRANSFER IN PARTICLES USING NOVEL COMPOUNDS | BIOSITE DIAGNOSTICS INCORPORATED (US) | 1995-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | MAOB 131/4885MAPK1 1767/4885ALDH1A1 1739/4885 |
| US-20200281951-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | MC2R, SLC6A2, CRH | MAOB 49/4885MAPK1 587/4885ALDH1A1 2027/4885 |
| US-10603331-B2 | Method of treating disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine | MC2R, PNMT, SLC6A2 | MAOB 50/4885MAPK1 1002/4885ALDH1A1 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.